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Abstract: Ghrelin is a gut hormone that stimulates food intake. In physiological conditions, ghrelin plasma levels rise with fasting and 
decrease after meals. Obese individuals have low fasting ghrelin levels that rise after food restriction, which is pointed out as a reason for 
the difficulty in maintaining weight loss. Some bariatric surgery procedures prevent rise in ghrelin levels with weight loss and this has 
been hypothesised to contribute to the long-term success of the treatment.  
The main goal of this study was to develop a safe and effective anti-ghrelin vaccine for obesity, through the chemical conjugation of 
ghrelin with a virus like particle, namely NS1 protein tubules from the Bluetongue Virus (BTV) using a hetero-bifunctional cross linker.  
Male adult C57BL/6 mice, with a normal weight and with diet-induced obesity (DIO), were randomized into six weight matched groups 
(n=6/group) and each group of mice received three intra-peritoneal injections with two weeks intervals, containing either 75 g of ghre-
lin-NS1 immunoconjugate, 75 g of NS1 or PBS. Our data show that immunized animals present increasing titres of anti-ghrelin antibod-
ies, while their cumulative food intake significantly decreased and energy expenditure was significantly enhanced, although there were 
no significative changes in body weight.Vaccinated DIO mice also displayed significant decrease of NPY gene expression in the basal 
hypothalamus reflecting a decrease in central orexigenic signals.  
This study suggests that this anti-ghrelin vaccine has a positive impact on energy homeostasis and may be an additional therapeutical tool 
to be used with diet and exercise for obesity treatment. 
Keywords: obesity, ghrelin, vaccine, virus-like particles, treatment.  
1. INTRODUCTION  
 Obesity is increasing worldwide [1, 2]. Obesity is associated 
with enhanced prevalence of several co-morbidities such as type 2 
diabetes mellitus, metabolic syndrome and cardiovascular diseases 
[3, 4] and weight loss improves or resolves several co-morbid con-
ditions associated with the disorder [5]. Clinicians have few tools to 
fight obesity. Diet and exercise are still the cornerstone for obesity 
treatment and current anti-obesity drugs achieve only relative short-
term weight loss [6] and are often followed by weight regain [7]. 
For morbid obesity, bariatric surgery is the only therapy that pro-
vides sustainable weight reduction [8]. Recent studies, suggest that 
weight loss attained after bariatric surgery is also due to endocrine 
effects of the surgery, which are able to interfere with appetite 
pathways by suppressing the rise in ghrelin levels that is usually 
observed after caloric deprivation [9, 10]. 
 As a proof of this concept, it has been demonstrated that inocu-
lation of monoclonal anti-ghrelin antibodies in mice inhibited acute 
ghrelin-mediated orexigenic effects but it was unable to change 
long-term food intake [11]. More recently, another study suggested 
that the use of a mixture of monoclonal antibodies targeting differ-
ent haptens, but not the antibodies individually, promotes not only 
an increase in energy expenditure but also a reduced deprivation-
induced food intake [12]. Ghrelin receptor antagonists, GSH-
R1demonstrated improved glucose tolerance, suppressed appetite 
and promoted weight loss [13], thus confirming the potential of 
ghrelin blocking as a potential treatment target for obesity. The 
suppression of endogenous ghrelin bioactivity with anti-ghrelin  
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vaccines using keyhole limpet hemocyanin (KLH) as carrier protein 
[14] or bovine serum albumin (BSA) [15], were also tested in mice 
and pigs, respectively. These vaccines were able to induce the de-
velopment of antibodies against the active form of ghrelin [14] and 
also to decrease body weight gain and fat mass [15]. However, 
these vaccines required the use of adjuvants, such as alum and Fre-
und incomplete adjuvant, which may be associated of inflammatory 
responses or have limited use in humans. 
 Virus-like particles (VLPs) have been used as immunogenic 
molecules in several recombinant vaccines in the last few years in 
order to induce the production of specific antibodies against en-
dogenous molecules with a preponderant role in chronic diseases 
[16], such as the anti-angiotensin vaccine developed for arterial 
hypertension treatment [17].  
 The main goal of this study was to develop an effective anti-
ghrelin vaccine using a chemical conjugate of active ghrelin with 
protein tubules of NS1 of the Bluetongue Virus (BTV) [18]. Al-
though this protein is not part of the viral capsid, NS1 tubules pos-
sess the same immunogenic characteristics as classical VLPs [19].  
2. MATERIALS AND METHODS 
2.1. Imunoconjugate Production 
 Tubules of NS1 protein of BTV were chemically conjugated to 
active ghrelin using the heterobifunctional cross linker EDC 
(Pierce, Illinois, USA), by incubating NS1 with an excess of EDC 
and N-hydroxysuccinimide (NHS), which activates the carboxyl 
groups present in the surface of the NS1 tubules. Ghrelin (H4862, 
Bachem, Germany) was added in excess and left to react at room 
temperature for 2 hours and the reaction was stopped by adding 
hydroxylamine. The cross linker in excess was removed by gel 
filtration chromatography using Zeba Columns (Pierce, Illinois, 
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USA). The newly formed immunoconjugate was recovered by di-
alysis in phosphate buffer solution (PBS) and the efficacy of the 
conjugation was assessed by SDS-PAGE. 
2.2. Animals 
 Thirty-six male adult C57BL6/J mice (Charles River, Barce-
lona, Spain), normal weight and with diet induced obesity mice 
(DIO) (n=18/group), were randomized into three weight-matched 
groups (n=6/group). Mice were maintained in standard animal 
house conditions with constant temperature (21±1ºC), humidity and 
12h controlled photoperiod (7h-19h). Normal weight mice were 
housed in groups (n=6 mice/cage) and DIO mice were housed indi-
vidually. Normal weight mice had unrestricted access to tap water 
and regular rat chow (SAFE – Scientific Animal Food & Engineer-
ing) and DIO mice to a hypercaloric diet with 60% of fat (Charles 
River, Barcelona, Spain), after weaning and until a week before the 
first immunization study when food was switched to regular rat 
chow (SAFE – Scientific Animal Food & Engineering). All proce-
dures were approved by the local Ethics Board for Animal Research 
and followed the European Union laws on animal protection 
(86/609/EC). 
2.3. Immunization Protocols 
 Mice received three intra-peritoneal (i.p.) injections with two 
week intervals, containing 500l of 75g of immunoconjugate, 
75g of NS1 protein alone or PBS. The additional control group 
inoculated with NSI only was included in order to distinguish the 
effects of the immune complex from NS1 ALONE.  
 A dose chosen after performing a dose-response study (data not 
shown) in which the 75 g dose of the immuneconjugate has dem-
onstrated to be adequate in inducing the development of anti-
ghrelin antibodies and reduce food intake.  
 Food intake was evaluated daily by weighing the remaining 
food in the hopper and 1, 2, 4, 8, 16 and 24h after each immuniza-
tion using a scale recording to the nearest 0.1 g (KB 5000-1, Kern, 
Germany). Body weight was assessed twice a week using a scale 
recording to the nearest 1 g (Monobloc, Mettler-Toledo, Switzer-
land). Mice were sacrificed two weeks after the last immunization. 
2.4. Evaluation of the Orexigenic Response to Exogenous Ghre-
lin 
 To evaluate the response to exogenous ghrelin, DIO mice re-
ceived 10 g of ghrelin (H4862, Bachem, Germany) i.p. or PBS on 
different occasions, while food intake was accessed 30, 60, 120 and 
180 minutes after the injections. These studies were performed 
before the start of the inoculation protocol while on hypercaloric 
diet and repeated a week after the introduction of standard diet.  
2.5. Evaluation of energy expenditure 
 Energy expenditure was accessed by indirect calorimetry. Mice 
were individually placed in a small grid cage to limit locomotor 
activity, which was placed into a sealed chamber containing a so-
dium hydroxide recipient to adsorb carbon dioxide. The lid of the 
chamber was sealed and pierced by a volumetric pipette to measure 
the volume of oxygen consumed. The time elapsed until 1ml was 
consumed was registered and repeated until 5 concordant values 
were obtained. The energy expenditure was then calculated consid-
ering that 4.82 kcal is the average energy released per litre of O2 
consumed. 
2.6. Anti-ghrelin Antibodies Titre Assessment 
 Anti-ghrelin antibodies titre was determined two weeks after 
each immunization in the serum of blood collected by submandibu-
lar vein puncture, by in house ELISA. Wells were coated with a 
3g/ml solution of ghrelin (H4862, Bachem, Germany) and the 
blocking of was done with TST+2%BSA solution. Serum samples 
were serially diluted in TST (10mM Tris (pH8.0), 150 mMNaCl, 
0.05% Tween 20) starting with a 1:30 dilution until a 1:3 dilution. 
Samples were allowed to react in the wells for 2 hours at room tem-
perature and IgG secondary antibody conjugated to Alcaline Phos-
phatase (1030-04, Southern Biotech, Birmingham, USA) in a 1:500 
dilution was then added for 1 hour. The wells were washed and the 
substrate p-p-Nitrophenyl phosphate in AP buffer (50mM Na2CO3, 
1mM MgCl2, pH 9.8) was added and the reaction was stopped with 
0.1 M EDTA (pH=8.0) solution. Absorbances were read immedi-
ately after the addition of the stopping solution at a wavelength of 
405 nm. Antibody titres were determined from the curves Abs= f 
(dilution). 
2.7. Hormone Measurements 
 At the end of the experiments, 12h fasted mice were anesthe-
tized with CO2 and blood was collected by cardiac puncture into 
chilled lithium heparin tubes containing a protease inhibitor (0.02 
ml Trasylol, Bayer, Portugal). Tubes were kept on ice and immedi-
ately centrifuged at 4ºC. Plasma was stored at -20ºC until the assays 
where performed. Plasma levels of active ghrelin (EZRGRA-90K, 
Linco Research, St. Charles, Mo, USA, range 25 - 2000 pg/mL), 
leptin (EZML-82K, Linco Research, St. Charles, Mo, USA, range 
0.2 - 30 ng/ml), insulin (EZRMI-13K, Linco Research, St. Charles, 
Mo, USA, range 0.2 - 10 ng/ml), growth hormone (EZRMGH-45K, 
Linco Research, St. Charles, Mo, USA, range 0.07–50 ng/mL), 
IGF-1 (E25, Mediagnost, Reutlingen, Germany, range 0.5 - 18 
ng/ml) and TNF- (Quantikine, R&D Systems, Abingdon, United 
Kingdom, range 15.6 - 1000 pg/ml) were determined by ELISA 
using specific commercial kits according to the manufacturer in-
structions. Blood glucose levels were analysed in the whole blood 
by the glucose oxidase method using a glucometer (One Touch 
Ultra, Lifescan, Johnson and Johnson, Milipitas, CA). Epididymal 
fat pads were also collected and weighed. 
2.8. Test for the Presence of Circulating and Deposits of Im-
mune Complexes 
 Microplate wells were coated with a 3 g/ ml solution of anti-
mouse ghrelin rabbit IgGs (Bachem, California, USA) and were 
kept overnight at 4º C. Blocking was done by addition of a 
TST+2%BSA solution. Serum samples were allowed to react in the 
wells for 2 hours at room temperature and then washed in TST 
10mM Tris (pH8.0), 150 mMNaCl, 0.05% Tween 20) buffer. The 
IgG secondary antibody conjugated to Alcaline Phosphatase (1030-
04, Southern Biotech, Birmingham, USA) was added at a 1:1000 
dilution and allowed to react for 1 hour. The substrate p-p-
Nitrophenyl phosphate in AP buffer (50mM Na2CO3, 1mM MgCl2, 
pH 9.8) was then added and the reaction was stopped with a 0.1 M 
EDTA solution. 
 To detect the presence of immune complexes deposits in the 
glomerular membrane, kidneys were collected, fixated in 10% buff-
ered formaldehyde, processed for inclusion in paraffin blocks and 
an immunohistochemisty for immunoglobulins using the avidin-
biotin-peroxidase (ABC) modified method was performed. Briefly, 
the endogenous peroxidases were blocked with a 0.3 solution of 
hydrogen peroxide in methanol, followed by incubation in a moist 
chamber with 1% BSA (Sigma-Aldrich, St. Louis, USA). Excess 
BSA was removed and microscope slides were incubated with rab-
bit anti-mouse antiserum (E0354, DakoCytomation, Denmark) at a 
1:200 dilution followed by the avidin-biotin-peroxidase complex 
(DakoCytomation, Denmark) and the reaction was revealed with 
diaminobenzidine. Finally, the slides were coloured with hematox-
ylin and mounted for observation on optic microscope. Spleens of 
the same animals were used as positive controls due to their con-
stant baseline production of antibodies. 
2.9. RNA Extraction and Real Time PCR 
 Two weeks after the third immunization, mice were sacrificed 
and the stomach fundus and the hypothalamus were recovered and 
immediately frozen by immersion in liquid nitrogen to evaluate 
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ghrelin, Neuropeptide Y (NPY) and Proopiomelanocortin (POMC) 
expression.  
 Total RNA was isolated from using RNeasy Mini Kit (Qiagen, 
Germany) according to the manufacturer’s instructions and 500ng 
of RNA was retrotranscribed into cDNA using High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, 
CA). 
 The RNA expression of ghrelin, NPY and POMC in hypo-
thalamus and/or stomach were studied by using TaqMan real-time 
PCR in Step One Plus system (Applied Biosystems, Foster City, 
CA) using specific primers and probes obtained from inventoried 
TaqMan Gene Expression Assays (Applied Biosystems, Foster 
City, CA). All reactions were carried out using the following cy-
cling parameters: 50 C for 2 min, 95 C for 10 min followed by 40 
cycles of 95 C for 15 sec, 60 C for 1 min. For the analysis of the 
data, the RNA level of the gene of interest was normalizing using 
18S GADPH for stomach and -actin for hypothalamus values ac-
cording with the 2-Ct method. 
2.10. Statistical Analysis 
 Statistical analysis was made using SPSS statistical package for 
Windows version 18.0. Comparison of the means between groups 
was made using One-Way ANOVA with post hoc Bonferroni cor-
rection or Kruskall-Wallis tests, as appropriate. Pearson test was 
used for the correlation study. Results are shown as mean ± stan-
dard error (Mean±SEM), unless otherwise specified. A p value of 
<0.05 was considered statistically significant.  
3. RESULTS 
3.1. Immunoconjugate Production  
 The immunoconjugate of active ghrelin and NS1 protein of 
BTV was produced and revealed in the SDS-PAGE by the slightly 
higher molecular weight of the immunoconjugate as compared to 
NS1 protein alone due to the low molecular weight of ghrelin 
(3.314 kDa) (Fig. 1).
Fig. (1). Silver stained SDS-PAGE showing Low Molecular Weight Mark-
ers on lane 1, NS1 protein alone on lane 2 and immunoconjugate on lane 3.  
3.2. In vivo Studies  
3.2.1. Food Intake and Body Weight  
 Normal weight mice treated with the immunoconjugate dis-
played a significant decrease in daily food intake (0.44 g NS1-Ghr 
vs 0.14 g PBS vs 0.16 g NS1, p<0.001, since the animals were 
group housed per cage there are no errors attached to the values) 
(Fig. 2A). In addition, after the first two inoculations, there was also 
an acute decrease, although without reaching statistical signifi-
cance, in food intake in the group of mice that received the immune 
conjugate when compared to the PBS control, corresponding to 
95.3% and 94.8% of the PBS control, respectively (Fig. 3A). There 
were no significant differences in body weight gain between the 
different groups of mice during the study span (3.83 g ± 0.40 g 
NS1-Ghr vs 5.00 g ± 0.26 g PBS vs 5.33 g ± 0.49 g NS1, p=NS). 
 In DIO mice, after changing from the hypercaloric to the stan-
dard diet, there was an increase in daily food intake followed by 
rapid stabilization (Fig. 2B). DIO mice inoculated with the im-
munoconjugate did not display a significant decrease in cumulative 
food intake when compared to controls (147.64±2.46 g NS1-Ghr, 
147.80±5.89 g NS1, 150.37±3.65 g PBS, p=NS), although there 
was a significant decrease of food intake in the 24 hours immedi-
ately after each inoculation of the immunoconjugate, corresponding 
to 66.16% (p=0.036), 82.22% (p=0.008) and 50.09 % (p=0.039) 
(Fig. 3B) of the food intake of the PBS group, after the three inocu-
lations, respectively. DIO mice body weight decreased in response 
to the change from the hypercaloric to the standard diet (13.84% 
compared to baseline), although after the inoculations, there were 
no significant differences in body weight among the different ex-
perimental groups (32.17 ± 0.872 g NS1-Ghr vs 31.33 ± 1.282 g 
NS1 vs 31.83 ± 0.833 g PBS, p=NS).  
A)
B)
Fig. (2). Mean daily food intake of normal weight (A) and DIO mice (B). 
Normal weight mice vaccinated with the immunoconjugate displayed a 
significant decrease in daily food intake (A); while DIO mice, displayed an 
initial increase in daily food intake after changing of hypercaloric to stan-
dard diet, which was followed by stabilization, there was no significative 
difference between vaccinated and control mice (B). 
3.2.2. Evaluation of the Orexigenic Response to Exogenous Ghre-
lin 
 DIO mice, while on a hypercaloric diet, did not present any 
significant increase in food intake after the administration of  
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A) 
Fig. (3). Graph displaying cumulative food intake in the first 24h after each 
immunization in normal weight (A) and DIO mice (B). Vaccinated normal 
weight mice, after the first two inoculations, depicted an acute decrease in 
food intake when compared to the PBS controls, corresponding to 95.3% 
and 94.8% of the PBS control, respectively (A). Vaccinated DIO mice also 
displayed a significant decrease of food intake in the first 24 hours after 
each inoculation of the immunoconjugate, corresponding to 66.16% 
(p=0.036), 82.22% (p=0.008) and 50.09 % (p=0.039) of the food intake of 
the PBS control group, respectively (B). 
exogenous ghrelin. However, one week after the introduction of the 
standard diet, DIO mice showed a significant increase in food in-
take in the first hour after the administration of exogenous ghrelin 
when compared to PBS (0.087±0.031 g ghrelin vs0.056±0.020 g 
PBS on hypercaloric diet, p=NS; 0.156±0.032 g ghrelin vs
0.062±0.016 g PBS on standard diet, p=0.019), in agreement with 
what has been previously reported (19). 
3.2.3. Anti-ghrelin Antibodies Titre Assessment 
 Normal weight mice inoculated with the immunoconjugate 
developed specific anti-ghrelin antibodies, with increasing titres 
after each inoculation, reaching a maximum of 1265±492 two 
weeks after the last inoculation. The control groups that received 
either NS1 protein alone or PBS presented basal titres of 332±114 
and 324±143, p=0.035, respectively, which were maintained 
throughout the study and were not altered by the immunizations, 
which suggests nonspecific bindings related to the detection method 
(Fig. 4A).
 DIO mice inoculated with the immunoconjugate also developed 
specific anti-ghrelin antibodies in increasing titres until reaching a 
maximum after the third inoculation in contrast with control groups 
that maintained their basal titres (2680±1197NS1-Ghr, 458±31 NS1 
and 257±78 PBS group, respectively, p=0.03) (Fig. 4B). 
3.2.4. Energy Expenditure 
 Energy expenditure was significantly higher in normal weight 
mice inoculated with immunoconjugate when compared with con-
trols (0.0146±0.001 kcal/h/kg NS1-Ghr, 0.0138±0.001 kcal/h/kg 
NS1, 0.0129±0.001 kcal/h/kg PBS, p=0.038). 
 DIO mice inoculated with the immunoconjugate also showed 
higher energy expenditure when compared to the control groups 
(0.0207±0.01 kcal/h/kg NS1-Ghr, 0.0140±0.002 kcal/h/kg NS1, 
0.0159±0.002 kcal/h/kg PBS; p=0,044, NS1-Ghr vs PBS and 
p=0,008, NS1-Ghr vs NS1).  
3.2.5. Hormone Measurements  
 Fasting plasma levels of active ghrelin were significantly higher 
in normal weight mice that received the immunoconjugate 
(361.3±79.9 pg/ml) when compared to control groups (186.9±14.8 
pg/ml NS1 and 114.1±27.9 pg/ml PBS, p=0.009).  
 DIO mice inoculated with the immunoconjugate also presented 
higher levels of fasting plasma ghrelin than the controls (429.63± 
179.27 pg/ NS1-Ghr, 147.29±53.17 pg/ml NS1, 105.88±27.76 
pg/ml PBS, p=NS) although not statistically significant. There were 
no significant differences in plasma levels of leptin, insulin, glu-
cose, growth hormone, IGF-1, or TNF- between the groups (Table 
1).
3.2.6. Immune Complexes in Circulation and in the Kidney 
 ELISA confirmed the presence of circulating immune com-
plexes of ghrelin-anti-ghrelin antibodies in the plasma of normal 
weight mice inoculated with the immune conjugate. There was also 
a positive correlation between ghrelin plasma levels and the titre of 
circulating immune complexes (r=0.846) (Fig .5). Search for im-
munoglobulins deposits in the kidney by immunohistochemistry 
failed to reveal any evidence of deposited immune complexes on 
the glomerular basement membranes. 
3.2.7. Expression of Ghrelin mRNA in the Gastric Fundus and of 
NPY and POMC in the Basal Hypothalamus 
 In normal weight mice, there was no significant difference in 
ghrelin expression in the gastric fundus between the three experi-
mental groups of mice (0.94±0.17 NS1-Ghr, 1.79±0.35 NS1, 
1.00±0.30 PBS, p=NS). There was also no significant difference in 
NPY expression in the basal hypothalamus between the study 
groups (1.32 ± 0.17 NS1-Ghr, 0.94 ± 0.10 NS1, 1.00 ± 0.20 PBS, 
p=NS). In contrast, POMC mRNA expression was significantly 
lower in mice inoculated with the immunoconjugate when com-
pared to controls (0.20±0.17 NS1-Ghr, 0.93±0.17 NS1, 1.00±0.10 
PBS, p<0.05). 
 In DIO mice the expression of ghrelin after normalization for 
GADPH expression in stomach cells was also not significantly 
different among the different study groups (1.27±0.30 NS1-Ghr, 
0.38±0.13 NS1,1.00±0.12 PBS, p=NS). However, DIO mice inocu-
lated with the immune conjugate had a lower expression of NPY in 
the basal hypothalamus when compared to control groups (0.59± 
0.09 NS1-Ghr, 1.03±0.12 NS1, 1.00±0.13 for PBS, p<0.05). The 
expression of POMC in the basal hypothalamus was not signifi-
cantly different between the different groups in study (1.04±0.14 
NS1-Ghr, 1.32±0.25 NS1, 1.00±0.12 PBS, p=NS). 
4. DISCUSSION 
 Obesity is nowadays a major public health problem [20, 21] for 
which there is a lack of medical therapeutic resources [6, 22]. 
 Ghrelin is a gastro-intestinal hormone that promotes food intake 
and decreases energy expenditure [23]. Ghrelin acts in the arcuate 
nucleus of the basal hypothalamus, stimulating the production and 
release of NPY and suppressing POMC [24]. NPY is the most po-
tent signal in the central nervous system that stimulates food intake 
and decreases energy expenditure, while POMC is a precursor pro-
tein that through proteolytic cleavage originates various peptides, 
among which -MSH that decreases appetite and increases energy 
expenditure [25-28].  
 Since ghrelin is the only orexigenic hormone identified so far, it 
has been pointed as a promising treatment target for obesity [29]. 
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Fig. (4). Anti-ghrelin antibody titres of normal weight (*p=0.035) (A) and DIO mice (*p=0.03) (B) after the immunizations and two weeks after the third im-
munization. Mice inoculated with the immunoconjugate developed specific anti-ghrelin antibodies in increasing titres, reaching a maximum after the third 
inoculation in comparison with control groups that maintained constant the basal titres. 
Fig. (5). Circulating immune complexes titres and plasma ghrelin levels. There was a positive correlation between ghrelin plasma levels and the titre of circu-
lating immune complexes (r=0.846). 
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Table 1. Fasting hormone and glucose plasma levels of normal weight and DIO mice. 
 Normal weight mice DIO mice 
 PBS NS1 Vaccine Sig. PBS NS1 Vaccine Sig. 
Ghrelin (pg/ml) 114.1 ± 27.9 186.9 ± 14.8 361.3 ± 79.9 p=0.009 105.9 ± 27.8 147.3 ± 53.2 429.6 ± 179.3 NS 
Leptin (ng/ml) 1.32 ± 0.23 0.98 ± 0.21 1.50 ± 0.61 NS 5.85 ± 0.93 5.15 ± 0.75 7.11 ± 0.39 NS 
Insulin (ng/ml) 0.35 ± 0.08 1.08 ± 0.63 0.41 ± 0.07 NS 1.31 ± 0.09 1.01 ± 0.13 1.27 ± 0.11 NS 
Growth hormone 
(ng/ml) 
2.65 ± 0.69 5.50 ± 2.44 2.57 ± 0.41 NS 2.36 ± 0.74 5.28 ± 1.95 4.13 ± 1.31 NS 
IGF-1 (ng/ml) 473.8 ± 68.6 561.7 ± 35.3 499.8 ± 62.1 NS 347.7 ± 17.9 387.4 ± 34.5 394.8 ± 21.1 NS 
Glucose (mg/dl) 86.5 ± 6.3 82.3 ± 8.2 76.3 ± 2.9 NS 156.3 ± 31.8 128.2 ± 15.0 121.8 ± 11.3 NS 
TNF- 0.30 ± 0.30 8.42 ± 4.22 1.65 ± 1.31 NS 45.59 ± 24.72 5.76 ± 4.44 21.34 ± 15.29 NS 
Several research groups have previously attempted ghrelin neutrali-
zation. Passive transfer of monoclonal anti-ghrelin antibodies was 
unable to change long-term food intake in mice [11]. Antibodies 
targeted to hydrolyze the octanoyl moiety of ghrelin to form des-
acyl ghrelin, which has no biological activity, resulted in increased 
metabolic rate and suppressed 6h re-feeding after 24h of food dep-
rivation in mice, but this approach would imply the need of periodic 
antibodies administration [30]. More recently, another study con-
cluded that an oligoclonal response is required to maintain in-
creased energy expenditure during fasting and deprivation-induced 
food intake as well as to reduce overall food intake upon refeeding 
[12]. Ghrelin receptor antagonists have also been tested, and GSH-
R1a decreased food intake, body weight and improved glucose 
tolerance due to increased glucose-dependent insulin secretion [13]. 
Anti-ghrelin vaccines using KLH or BSA as immunogenic sub-
stances decreased body weight gain by decreasing feed efficiency in 
rats [14] and food intake and body weight in pigs [15]. However, 
these anti-ghrelin vaccination and neutralization strategies present 
several limitations when applied to humans because of the need to 
use adjuvants, the risk of exacerbated immune response against an 
endogenous substance and in the case of passive immunization, 
acquired tolerance and lack of long-term effect. When compared 
with classic immunization techniques, VLPs are safe due to the lack 
of genetic material, since VLPs consist of viral proteins only that 
prevents a possible reversion to a pathogenic phenotype, induce an 
efficient B cell activation, since the highly repetitive nature of these 
structures has the advantage of allowing B cell receptor cross-
linking due to the ordered presentation of epitopes in molecule 
surface, and a high immunogenicity regardless of the route of the 
immunization, which allows the use of a low number of immuniza-
tions and a lower quantity of vaccine, making this type of vaccina-
tion protocol more efficient and cost-effective [31].  
 The main goal of the current study was to develop a safer and 
more effective anti-ghrelin vaccine that could be used for human 
treatment. For that we developed an immunoconjugate composed of 
ghrelin and NS1 protein of BTV. The choice of NS1 tubules as 
VLP-like carrier protein was driven by its previous use as a distri-
bution system for molecules of prophylactic vaccines against com-
mon human infectious diseases, such as proteins of the foot-and-
mouth disease and influenza A virus [19, 32]. 
 The ability of the vaccine to trigger an immune response was 
tested in normal weight and DIO male mice that developed increas-
ing titres of specific anti-ghrelin antibodies, confirming the hy-
pothesis that a vaccine consisting of immunoconjugate only is able 
to trigger an immune response without the need adjuvants. Fur-
thermore, antibodies titres attained after the immunization protocol 
were not very high, when compared to antibodies titres after com-
mon infectious diseases, which is also reassuring in safety concerns, 
since complete neutralization of ghrelin was not the purpose of an 
anti-ghrelin vaccination strategy for obesity treatment as ghrelin 
also intervenes in several key biological processes besides appetite 
regulation, such as growth hormone secretion, gastro-intestinal and 
cardiovascular functions [29]. In the present study we chose to use 
only male mice, to allow the characterization of the effects of the 
vaccine irrespective of other hormonal influences such as the ovar-
ian cycles. The decision to use diet induced obesity mice (DIO) that 
develop obesity in result of the sedentary lifestyle and increased 
caloric intake, resided in the fact that this obesity animal model is 
the one that more accurately reflects the most common cause of 
obesity in order to allow the evaluation of the interaction between 
ghrelin and anorexigenic pathways, which compared to the ob/ob or 
the db/db mouse, which present monogenetic causes of obesity that 
are rare in the human setting.  
 Vaccinated mice presented acute decreases in food intake in the 
24h immediately after the immunizations that were more pro-
nounced in DIO mice. This acute decrease in food intake, cannot be 
attributed to an immune response given the short time elapsed after 
the inoculation; and because mice presented no signs of sickness or 
changes in TNF- levels, an alternative explanation could be a se-
questration of free plasma ghrelin by the immunoconjugate. Al-
though unlikely, as the excess of crosslinker was chemically neu-
tralized before inoculating the mice. Since mice daily and cumula-
tive food intake over the study time span was not significantly dif-
ferent in vaccinated mice compared to controls, it suggests the need 
for optimizing the immunization protocol herein used, namely the 
time gap between the inoculations and the amount of anti-ghrelin 
vaccine administration. 
 Vaccinated mice showed significantly higher energy expendi-
ture than the animals of the groups that received either NS1 protein 
alone or PBS. Higher energy expenditure usually translates into 
greater ease of weight loss and maintenance. Ghrelin is known to 
suppress energy metabolism and ghrelin replacement partially re-
verses the reduction in body weight and body fat in gastrectomised 
mice [33]. Ghrelin has been shown to have a long-term effect on 
energy homeostasis by increasing the respiratory quotient, through 
decreasing utilisation of fat as energy [34]. In addition, ghrelin 
knockout mice compared to wild type mice present no change in 
food intake but have a decreased respiratory quotient when fed with 
high fat diet, suggesting that endogenous ghrelin plays a more 
prominent role in determining the type of metabolic substrate that is 
used for maintenance of energy balance, than in the regulation of 
food intake [35]. Although vaccinated animals gained less weight 
when compared with control animals, this difference failed to reach 
statistical significance, which may be explained by the short follow-
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up time or the activation of compensatory mechanisms of energy 
homeostasis pathways.  
 Paradoxically, vaccinated mice had higher ghrelin levels com-
pared to controls. Given that these increased levels of ghrelin did 
not appear to have a biological effect, we hypothesize that circulat-
ing ghrelin could be in the form of immune complexes of ghrelin-
anti-ghrelin, which was confirmed. Previous reports on anti-ghrelin 
vaccines have also documented an increase of ghrelin in immunized 
animals, although the presence of circulating immunocomplexes 
has not been documented [36]. The presence of circulating im-
munocomplexes, which could be due to a lower rate of elimination, 
raised the concern of renal toxicity due to the deposition in the 
glomerular basement membrane that has been excluded. Since there 
was no difference in ghrelin expression in the stomach, ghrelin 
appears to be synthesized in immunized animals as in controls and 
after neutralization of ghrelin biological activity there is no up regu-
lation of ghrelin expression in order to maintain the homeostasis. 
 In vaccinated normal weight mice there were no significant 
differences in the genetic expression of NPY gene in the basal hy-
pothalamus in comparison to control mice. However, in vaccinated 
DIO mice there was a significant decrease of NPY gene expression 
in the basal hypothalamus compared with controls reflecting a de-
crease in central orexigenic signals [37]. The expression of POMC 
in the basal hypothalamus was significantly lower in vaccinated 
normal weight animals compared to controls that could represent a 
compensatory mechanism to the decreased peripheral orexigenic 
signals in order to prevent the reduction in feeding threshold of 
normal weight mice, which could also explain why these findings 
only occurred in the normal weight mice but not on DIO mice. 
 Ghrelin is a growth hormone secretagogue [29] and ghrelin 
neutralization could induce alterations in GH/IGF-1 axis. Since this 
vaccine appears to have no effect in GH and IGF-1 levels, this sug-
gests that our vaccine is unlikely to cause endocrine adverse effects 
on the growth hormone axis. 
 The regulatory mechanisms of energy homeostasis and appetite 
control are very complex processes that include highly redundant 
signalling pathways [24].Therefore, it is possible that the lack of 
significant differences in some biological parameters, such as food 
intake and body weight maybe due to activation of compensatory 
mechanisms for the decrease in available active ghrelin similar to 
that which occurs in ghrelin knockout mice [35, 38]. 
 One of the major acquisitions of the research work described in 
this paper was the demonstration of the capacity of this vaccine to 
efficiently induce the production of antibodies against an endoge-
nous molecule without the requirement to use adjuvants and the 
ability to neutralize some of ghrelin biological effects. Furthermore, 
this vaccine appears to be well tolerated by the animals and there 
were no signs of inflammatory reaction or toxicity. The production 
of anti-ghrelin antibodies was effective in decreasing acute food 
intake and increasing energy expenditure in the vaccinated animals 
compared to control animals, which are important contributions to 
establish a negative energy balance and thus promote weight loss. 
CONCLUSION 
 In conclusion, these results suggest that this anti-ghrelin vac-
cine has a positive impact on energy homeostasis and may be a 
useful tool for obesity treatment.  
CONFLICT OF INTEREST 
 The authors confirm that this article content has no conflicts of 
interest. 
ACKNOWLEDGEMENTS 
 Author Contributions: S.A. researched data and wrote manu-
script; F.P, A.M.R. and M.C.C. researched data, F.F.C. contributed 
to discussion and reviewed/edited manuscript, P.R reviewed/edited 
manuscript and M.P.M. researched data and reviewed/edited manu-
script. 
 We thank Luísa Guardão, ICBAS-UP, for support with animal 
work; Madalena Costa, ICBAS-UP, for technical support with im-
munohistochemistry, Luzia Teixeira, ICBAS-UP, for technical 
support with ELISA studies and Tiago Guedes, ICBAS-UP, for 
technical help with ELISA assays and animal work. UMIB is 
funded by grants from FCT POCTI/FEDERFcomp-01-0124-
FEDER-015893 and Project Grant EXPL/BIM-MET/0618/2012. 
M.C.C. is funded by the Xunta de Galicia through a research-staff 
contract “Angeles Alvarinño. Fondo de Investigación Sanitaria. 
Ministerio de Sanidad y Consumo. Instituto Carlos III. IN-
TRASALUD Program PI10/02464. Fundación Lilly. 
REFERENCES
[1] WHO. DIET, NUTRITION AND THE PREVENTION OF 
CHRONIC DISEASES 2003. Available at 
http://www.who.int/mediacentre/news/releases/2003/pr20/en/ . 
Acessed on 3 July 2009. 2003. 
[2] WHO. Obesity and overweight fact sheet Nº311. Available at 
http://www.who.int/mediacentre/factsheets/fs311/en/print.html. 
Acessed 3 July 2009. 2006. 
[3] Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical 
spending attributable to obesity: payer-and service-specific esti-
mates. Health affairs 2009; 28: w822-31. 
[4] Rappange DR, Brouwer WB, Hoogenveen RT, Van Baal PH. 
Healthcare costs and obesity prevention: drug costs and other sec-
tor-specific consequences. PharmacoEconomics 2009; 27: 1031-44. 
[5] Pi-Sunyer FX. The obesity epidemic: pathophysiology and conse-
quences of obesity. Obes Res 2002; 10 Suppl 2: 97S-104S. 
[6] Bray GA. Lifestyle and pharmacological approaches to weight loss: 
efficacy and safety. J Clin Endocrinol Metab 2008; 93: S81-8. 
[7] Clinical Guidelines on the Identification, Evaluation, and Treat-
ment of Overweight and Obesity in Adults--The Evidence Report. 
National Institutes of Health. Obesity research 1998; 6 Suppl 2: 
51S-209S. 
[8] Bult MJ, van Dalen T, Muller AF. Surgical treatment of obesity. 
Eur J Endocrinol 2008; 158: 135-45. 
[9] Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels 
after diet-induced weight loss or gastric bypass surgery. N Engl J 
Med 2002; 346: 1623-30. 
[10] Monteiro MP, Ribeiro AH, Nunes AF, et al. Increase in ghrelin 
levels after weight loss in obese Zucker rats is prevented by gastric 
banding. Obes Surg 2007; 17: 1599-607. 
[11] Lu SC, Xu J, Chinookoswong N, et al. An acyl-ghrelin-specific 
neutralizing antibody inhibits the acute ghrelin-mediated orexigenic 
effects in mice. Mol Pharmacol 2009; 75: 901-7. 
[12] Zakhari JS, Zorrilla EP, Zhou B, Mayorov AV, Janda KD. Oligo-
clonal antibody targeting ghrelin increases energy expenditure and 
reduces food intake in fasted mice. Molecular pharmaceutics 2012; 
9: 281-9. 
[13] Esler WP, Rudolph J, Claus TH, et al. Small-molecule ghrelin 
receptor antagonists improve glucose tolerance, suppress appetite, 
and promote weight loss. Endocrinology 2007; 148: 5175-85. 
[14] Zorrilla EP, Iwasaki S, Moss JA, et al. Vaccination against weight 
gain. Proc Natl Acad Sci USA 2006; 103: 13226-31. 
[15] Vizcarra JA, Kirby JD, Kim SK, Galyean ML. Active immuniza-
tion against ghrelin decreases weight gain and alters plasma con-
centrations of growth hormone in growing pigs. Domest Anim En-
docrinol 2007; 33: 176-89. 
[16] Jennings GT, Bachmann MF. Immunodrugs: therapeutic VLP-
based vaccines for chronic diseases. Annu Rev Pharmacol Toxicol 
2009; 49: 303-26. 
[17] Brown MJ. Therapeutic potential of vaccines in the management of 
hypertension. Drugs 2008; 68: 2557-60. 
[18] Hewat EA, Booth TF, Wade RH, Roy P. 3-D reconstruction of 
bluetongue virus tubules using cryoelectron microscopy. J Struct 
Biol 1992; 108: 35-48. 
[19] Ghosh MK, Borca MV, Roy P. Virus-derived tubular structure 
displaying foreign sequences on the surface elicit CD4+ Th cell and 
protective humoral responses. Virology 2002; 302: 383-92. 
[20] Moayyedi P. The epidemiology of obesity and gastrointestinal and 
other diseases: an overview. Dig Dis Sci 2008; 53: 2293-9. 
6558    Current Pharmaceutical Design, 2013, Vol. 19, No. 36 Andrade et al. 
[21] Puska P, Nishida, C., Porter, D., World Health Organization. Obe-
sity and overweight. Available at 
http://www.who.int/dietphysicalactivity/publications/facts/obesity/e
n/print.html. Acessed on 3 July 2009 2006. 
[22] Snow V, Barry P, Fitterman N, Qaseem A, Weiss K. Pharma-
cologic and surgical management of obesity in primary care: a 
clinical practice guideline from the American College of Physi-
cians. Ann Intern Med 2005; 142: 525-31. 
[23] De Vriese C, Delporte C. Ghrelin: a new peptide regulating growth 
hormone release and food intake. Int J Biochem Cell Biol 2008; 40: 
1420-4. 
[24] Cone RD, Cowley MA, Butler AA, Fan W, Marks DL, Low MJ. 
The arcuate nucleus as a conduit for diverse signals relevant to en-
ergy homeostasis. Int J Obes Relat Metab Disord 2001; 25 Suppl 5: 
S63-7. 
[25] Chee MJ, Colmers WF. Y eat? Nutrition 2008; 24: 869-77. 
[26] Millington GW. The role of proopiomelanocortin (POMC) neu-
rones in feeding behaviour. Nutr Metab (Lond) 2007; 4: 18. 
[27] Suzuki K, Simpson KA, Minnion JS, Shillito JC, Bloom SR. The 
role of gut hormones and the hypothalamus in appetite regulation. 
Endocr J; 57: 359-72. 
[28] Williams G, Harrold JA, Cutler DJ. The hypothalamus and the 
regulation of energy homeostasis: lifting the lid on a black box. 
Proc Nutr Soc 2000; 59: 385-96. 
[29] Kojima M, Kangawa K. Ghrelin: structure and function. Physiol 
Rev 2005; 85: 495-522. 
[30] Mayorov AV, Amara N, Chang JY, et al. Catalytic antibody degra-
dation of ghrelin increases whole-body metabolic rate and reduces 
refeeding in fasting mice. Proc Natl Acad Sci USA 2008; 105: 
17487-92. 
[31] Lechner F, Jegerlehner A, Tissot AC, et al. Virus-like particles as a 
modular system for novel vaccines. Intervirology 2002; 45: 212-7. 
[32] Mikhailov M, Monastyrskaya K, Bakker T, Roy P. A new form of 
particulate single and multiple immunogen delivery system based 
on recombinant bluetongue virus-derived tubules. Virology 1996; 
217: 323-31. 
[33] Dornonville de la Cour C, Lindqvist A, Egecioglu E, et al. Ghrelin 
treatment reverses the reduction in weight gain and body fat in 
gastrectomised mice. Gut 2005; 54: 907-13. 
[34] Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in 
rodents. Nature 2000; 407: 908-13. 
[35] Wortley KE, Anderson KD, Garcia K, et al. Genetic deletion of 
ghrelin does not decrease food intake but influences metabolic fuel 
preference. Proc Natl Acad Sci USA 2004; 101: 8227-32. 
[36] Kellokoski E, Kummu O, Serpi R, et al. Ghrelin vaccination de-
creases plasma MCP-1 level in LDLR(-/-)-mice. Peptides 2009; 30: 
2292-300. 
[37] Kalra SP, Dube MG, Sahu A, Phelps CP, Kalra PS. Neuropeptide 
Y secretion increases in the paraventricular nucleus in association 
with increased appetite for food. Proc Natl Acad Sci USA 1991; 
88: 10931-5. 
[38] De Smet B, Depoortere I, et al. Energy homeostasis and gastric 
emptying in ghrelin knockout mice. J Pharmacol Exp Ther 2006; 
316: 431-9. 
Received: May 24, 2013               Accepted: July 9, 2013 
